<?xml version="1.0" encoding="UTF-8"?><CONCLUSION NNC="YES" xmlns:fmx="http://opoce" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://formex.publications.europa.eu/schema/formex-05.55-20141201.xd"><BIB.CONCLUSION><REF.CASE FILE="n.a."><NO.CASE>C‑672/15</NO.CASE></REF.CASE><NO.CELEX>62015CC0672</NO.CELEX><NO.ECLI ECLI="ECLI:EU:C:2016:961">EU:C:2016:961</NO.ECLI><NO.SEQ>0001</NO.SEQ><PAGE.FIRST.ECR>1</PAGE.FIRST.ECR><PAGE.SEQ>1</PAGE.SEQ><PAGE.LAST.ECR>16</PAGE.LAST.ECR><PAGE.TOTAL>16</PAGE.TOTAL></BIB.CONCLUSION><CURR.TITLE><PAGE.HEADER><P>OPINION OF MR BOBEK — CASE C‑672/15</P><P>NORIA DISTRIBUTION</P></PAGE.HEADER></CURR.TITLE><TITLE><TI><P><HT TYPE="UC">Opinion of Advocate General</HT></P><P><HT TYPE="UC">Bobek</HT></P><P>delivered on <DATE ISO="20161215">15 December 2016</DATE><NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0001"><P>Original language: English.</P></NOTE></P></TI><STI><P><HT TYPE="BOLD">Case C‑672/15</HT></P><P><HT TYPE="BOLD">Procureur de la République</HT></P><P><HT TYPE="BOLD">v</HT></P><P><HT TYPE="BOLD">Noria Distribution SARL</HT></P><P>(Request for a preliminary ruling from the Tribunal de grande instance de Perpignan (Regional Court, Perpignan, France))</P></STI></TITLE><INDEX><KEYWORD>Food supplements</KEYWORD><KEYWORD>Vitamins and minerals</KEYWORD><KEYWORD>Mutual recognition</KEYWORD><KEYWORD>Fixing of maximum daily doses</KEYWORD></INDEX><CONTENTS.CONCLUSION><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">I –</HT></NO.P><TXT><HT TYPE="BOLD">Introduction</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0001"><NO.P>1.</NO.P><TXT>Noria Distribution SARL (<QUOT.START CODE="2018" REF.END="QE0001" ID="QS0001"/>Noria<QUOT.END REF.START="QS0001" CODE="2019" ID="QE0001"/>) is being prosecuted for having sold in France food supplements containing vitamins and minerals in quantities exceeding maxima set under French law. Noria does not deny doing so. However, it argues in response that those maxima are not valid because they were set in breach of EU law. Noria adds that it produces and sells the same products lawfully in other Member States. In its view, French law is also in violation of EU law because it does not contain any simplified mutual recognition procedure that would allow Noria to import its products into France.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0002"><NO.P>2.</NO.P><TXT>The national court hearing the case asks whether the absence of a simplified mutual recognition procedure is indeed compatible with EU law. The national court also enquires whether certain aspects of the way the maxima in question were fixed are compatible with EU law. Specifically it wishes to ascertain (a) whether, in setting those maxima, account should be taken not only of national but also international scientific research and (b) whether nutrients can be grouped and maxima expressed as multiples of recommended daily allowances.</TXT></NP.ECR></GR.SEQ><?PAGE NO="2"?><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">II –</HT></NO.P><TXT><HT TYPE="BOLD">Legal framework</HT></TXT></NP></TI></TITLE><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>A –</NO.P><TXT><HT TYPE="ITALIC">EU law</HT></TXT></NP></TI></TITLE><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>1.</NO.P><TXT>Directive 2002/46</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0003"><NO.P>3.</NO.P><TXT>Recital 13 of Directive 2002/46/EC<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0002"><P>Directive of the European Parliament and of the Council of <DATE ISO="20020610">10 June 2002</DATE> on the approximation of the laws of the Member States relating to food supplements (<REF.DOC.OJ COLL="L" NO.OJ="183" PAGE.FIRST="51" DATE.PUB="2002">OJ 2002 L 183, p. 51</REF.DOC.OJ>).</P></NOTE>(<QUOT.START CODE="2018" REF.END="QE0002" ID="QS0002"/>the Directive<QUOT.END REF.START="QS0002" CODE="2019" ID="QE0002"/>) states that excessive intake of vitamins and minerals can have adverse effects on health, justifying the setting of maximum levels. Recital 14 states that:</TXT><P><QUOT.S LEVEL="1"><CONSID><P><QUOT.START CODE="2018" REF.END="QE0003" ID="QS0003"/>When maximum levels are set, therefore, account should be taken of the upper safe levels of the vitamins and minerals, as established by scientific risk assessment based on generally acceptable scientific data, and of intakes of those nutrients from the normal diet. Due account should also be taken of reference intake amounts when setting maximum levels.<QUOT.END REF.START="QS0003" CODE="2019" ID="QE0003"/></P></CONSID></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0004"><NO.P>4.</NO.P><TXT>Article 2 of the Directive defines the following terms:</TXT><P><QUOT.S LEVEL="1"><ALINEA><LIST TYPE="OTHER"><ITEM><NP><NO.P><QUOT.START CODE="2018" REF.END="QE0004" ID="QS0004"/>(a)</NO.P><TXT><QUOT.START CODE="201C" REF.END="QE0005" ID="QS0005"/>food supplements<QUOT.END REF.START="QS0005" CODE="201D" ID="QE0005"/> means foodstuffs the purpose of which is to supplement the normal diet and which are concentrated sources of nutrients or other substances with a nutritional or physiological effect, alone or in combination, marketed in dose form, namely forms such as capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other similar forms of liquids and powders designed to be taken in measured small unit quantities;</TXT></NP></ITEM><ITEM><NP><NO.P>(b)</NO.P><TXT><QUOT.START CODE="201C" REF.END="QE0006" ID="QS0006"/>nutrients<QUOT.END REF.START="QS0006" CODE="201D" ID="QE0006"/> means the following substances:</TXT><P><LIST TYPE="roman"><ITEM><NP><NO.P>(i)</NO.P><TXT>vitamins,</TXT></NP></ITEM><ITEM><NP><NO.P>(ii)</NO.P><TXT>minerals.<QUOT.END REF.START="QS0004" CODE="2019" ID="QE0004"/></TXT></NP></ITEM></LIST></P></NP></ITEM></LIST></ALINEA></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0005"><NO.P>5.</NO.P><TXT>Article 3 provides that:</TXT><P><QUOT.S LEVEL="1"><ALINEA><QUOT.START CODE="2018" REF.END="QE0007" ID="QS0007"/>Member States shall ensure that food supplements may be marketed within the Community only if they comply with the rules laid down in this Directive.<QUOT.END REF.START="QS0007" CODE="2019" ID="QE0007"/></ALINEA></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0006"><NO.P>6.</NO.P><TXT>Article 4 states that:</TXT><P><QUOT.S LEVEL="1"><PARAG IDENTIFIER="004.001"><NO.PARAG><QUOT.START CODE="2018" REF.END="QE0008" ID="QS0008"/>1.</NO.PARAG><ALINEA>Only vitamins and minerals listed in Annex I, in the forms listed in Annex II, may be used for the manufacture of food supplements, subject to paragraph 6.</ALINEA></PARAG><P>…</P><?PAGE NO="3"?><PARAG IDENTIFIER="004.006"><NO.PARAG>6.</NO.PARAG><ALINEA><P>By way of derogation from paragraph 1 and until <DATE ISO="20091231">31 December 2009</DATE>, Member States may allow in their territory the use of vitamins and minerals not listed in Annex I, or in forms not listed in Annex II, provided that:</P><NP><NO.P>(a)</NO.P><TXT>the substance in question is used in one or more food supplements marketed in the Community on the date of entry into force of this Directive,</TXT></NP><NP><NO.P>(b)</NO.P><TXT>the European Food Safety Authority has not given an unfavourable opinion in respect of the use of that substance, or its use in that form, in the manufacture of food supplements, on the basis of a dossier supporting use of the substance in question to be submitted to the Commission by the Member State not later than <DATE ISO="20050712">12 July 2005</DATE>.</TXT></NP></ALINEA></PARAG><PARAG IDENTIFIER="004.007"><NO.PARAG>7.</NO.PARAG><ALINEA>Notwithstanding paragraph 6, Member States may, in compliance with the rules of the Treaty, continue to apply existing national restrictions or bans on trade in food supplements containing vitamins and minerals not included in the list in Annex I or in the forms not listed in Annex II.<QUOT.END REF.START="QS0008" CODE="2019" ID="QE0008"/></ALINEA></PARAG></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0007"><NO.P>7.</NO.P><TXT>Article 5 foresees that:</TXT><P><QUOT.S LEVEL="1"><PARAG IDENTIFIER="005.001"><NO.PARAG><QUOT.START CODE="2018" REF.END="QE0009" ID="QS0009"/>1.</NO.PARAG><ALINEA><P>Maximum amounts of vitamins and minerals present in food supplements per daily portion of consumption as recommended by the manufacturer shall be set, taking the following into account:</P><LIST TYPE="alpha"><ITEM><NP><NO.P>(a)</NO.P><TXT>upper safe levels of vitamins and minerals established by scientific risk assessment based on generally accepted scientific data, taking into account, as appropriate, the varying degrees of sensitivity of different consumer groups;</TXT></NP></ITEM><ITEM><NP><NO.P>(b)</NO.P><TXT>intake of vitamins and minerals from other dietary sources.</TXT></NP></ITEM></LIST></ALINEA></PARAG><PARAG IDENTIFIER="005.002"><NO.PARAG>2.</NO.PARAG><ALINEA>When the maximum levels referred to in paragraph 1 are set, due account should also be taken of reference intakes of vitamins and minerals for the population.</ALINEA></PARAG><PARAG IDENTIFIER="005.003"><NO.PARAG>3.</NO.PARAG><ALINEA>To ensure that significant amounts of vitamins and minerals are present in food supplements, minimum amounts per daily portion of consumption as recommended by the manufacturer shall be set, as appropriate.</ALINEA></PARAG><PARAG IDENTIFIER="005.004"><NO.PARAG>4.</NO.PARAG><ALINEA>The maximum and minimum amounts of vitamins and minerals referred to in paragraphs 1, 2 and 3 shall be adopted by the Commission. Those measures, designed to amend non-essential elements of this Directive by supplementing it, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 13(3).<QUOT.END REF.START="QS0009" CODE="2019" ID="QE0009"/></ALINEA></PARAG></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0008"><NO.P>8.</NO.P><TXT>Article 11 provides that:</TXT><P><QUOT.S LEVEL="1"><PARAG IDENTIFIER="011.001"><NO.PARAG><QUOT.START CODE="2018" REF.END="QE0010" ID="QS0010"/>1.</NO.PARAG><ALINEA>Without prejudice to Article 4(7), Member States shall not, for reasons related to their composition, manufacturing specifications, presentation or labelling, prohibit or restrict trade in products referred to in Article 1 which comply with this Directive and, where appropriate, with Community acts adopted in implementation of this Directive.</ALINEA></PARAG><PARAG IDENTIFIER="011.002"><NO.PARAG>2.</NO.PARAG><ALINEA>Without prejudice to the Treaty, in particular Articles 28 and 30 thereof, paragraph 1 shall not affect national provisions which are applicable in the absence of Community acts adopted under this Directive.<QUOT.END REF.START="QS0010" CODE="2019" ID="QE0010"/></ALINEA></PARAG></QUOT.S></P></NP.ECR></GR.SEQ></GR.SEQ><?PAGE NO="4"?><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>B –</NO.P><TXT><HT TYPE="ITALIC">National law</HT></TXT></NP></TI></TITLE><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>1.</NO.P><TXT>Decree</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0009"><NO.P>9.</NO.P><TXT>Décret n<HT TYPE="SUP">o</HT>2006-352 du <DATE ISO="20060320">20 mars 2006</DATE> relatif aux compléments alimentaires (Decree No 2006-352 of <DATE ISO="20060320">20 March 2006</DATE> on food supplements) (<QUOT.START CODE="2018" REF.END="QE0011" ID="QS0011"/>the Decree<QUOT.END REF.START="QS0011" CODE="2019" ID="QE0011"/>) transposes the Directive into French law. According to its Article 5, vitamins and minerals can be used in the manufacture of food supplements under conditions to be laid down by ministerial order.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0010"><NO.P>10.</NO.P><TXT>Article 6 of the Decree provides that <HT TYPE="ITALIC">substances with a nutritional or physiological effect</HT> can be used in food supplements essentially if they have been authorised by certain national procedures including by application of Article 16 of the Decree.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0011"><NO.P>11.</NO.P><TXT>Article 7 of the Decree states that <HT TYPE="ITALIC">plants and preparations of plants</HT> can be used in food supplements essentially if they are traditionally recognised as foodstuffs, or have been authorised by certain national procedures including by application of Article 16 of the Decree.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0012"><NO.P>12.</NO.P><TXT>Article 16 of the Decree concerns food supplements containing <HT TYPE="ITALIC">substances with a nutritional or physiological effect</HT> or <HT TYPE="ITALIC">plants or preparations of plants</HT>, which have been legally marketed in other Member States and which are being placed on the market in France for the first time.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0003"><P>Confirmed by the French Government in its written submissions.</P></NOTE> It foresees a certain procedure for authorisation of such substances, where they have not already been authorised under Article 6 or 7 (<QUOT.START CODE="2018" REF.END="QE0012" ID="QS0012"/>Article 16 evaluation procedure<QUOT.END REF.START="QS0012" CODE="2019" ID="QE0012"/>).</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0013"><NO.P>13.</NO.P><TXT>Under the Article 16 evaluation procedure, the importer must provide, among others, any data in its possession that is useful for the evaluation of the relevant substance.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0004"><P>The original French text refers to <QUOT.START CODE="2018" REF.END="QE0013" ID="QS0013"/>… toutes les données en sa possession utiles à l’appréciation de la substance …<QUOT.END REF.START="QS0013" CODE="2019" ID="QE0013"/>.</P></NOTE> The competent national authority decides, within two months and on the basis of the dossier submitted, whether to authorise the product or refuse authorisation. Any refusal must be justified, either for reasons of incompleteness of the dossier, or for scientific reasons, in particular, due to risk for human health.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0014"><NO.P>14.</NO.P><TXT>Articles 17 and 18 create a procedure for the revision of the maximum amounts of vitamins and minerals contained in food supplements, that have been fixed by decree adopted in application of Article 5.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0005"><P>Pending the fixing of maxima under the Directive.</P></NOTE> Such requests are to be made to the competent national authority, which decides following consultation with the relevant national scientific body.</TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>2.</NO.P><TXT>Order</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0015"><NO.P>15.</NO.P><TXT>Pursuant to Article 5 of the Decree, a ministerial order dated <DATE ISO="20060509">9 May 2006</DATE> was adopted (<QUOT.START CODE="2018" REF.END="QE0014" ID="QS0014"/>the Order<QUOT.END REF.START="QS0014" CODE="2019" ID="QE0014"/>). Annexes I and II of that order include a list of vitamins and minerals that can be used in the manufacture of food supplements and the forms in which they can be used. Annex III sets out maximum daily doses for those vitamins and minerals that cannot be exceeded.</TXT></NP.ECR></GR.SEQ></GR.SEQ></GR.SEQ><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">III –</HT></NO.P><TXT><HT TYPE="BOLD">Facts, procedure and questions referred</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0016"><NO.P>16.</NO.P><TXT>Noria markets a number of food supplements in EU Member States.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0006"><P>The order for reference does not give any detail in this regard. It states that the marketing of the relevant products <QUOT.START CODE="2018" REF.END="QE0015" ID="QS0015"/>has been agreed to in the other Member States<QUOT.END REF.START="QS0015" CODE="2019" ID="QE0015"/>.</P></NOTE> Some of those products were exported to and marketed in France. They included supplements containing daily doses exceeding certain maxima foreseen in national law (as provided for in the Order).</TXT></NP.ECR><?PAGE NO="5"?><NP.ECR IDENTIFIER="NP0017"><NO.P>17.</NO.P><TXT>In criminal proceedings before the Tribunal de grande instance de Perpignan (Regional Court, Perpignan, France) (the referring court), Noria was prosecuted for having marketed in France food supplements with recommended daily doses exceeding those maxima.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0018"><NO.P>18.</NO.P><TXT>According to the order for reference, Noria had previously requested from the competent national authority an authorisation to market its food supplements in France. That request was refused. Noria appealed before the national administrative courts. Its appeal was rejected at first instance in November 2009. The first instance judgment was upheld by the Cour administrative d’appel de Marseille (Administrative Court of Appeal, Marseille, France) in May 2014.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0019"><NO.P>19.</NO.P><TXT>In parallel to the above events, proceedings were brought before the French Conseil d’État (Council of State) by various producers for the annulment of the Order. In the context of that case, a reference was made to this Court raising various questions about the compatibility of that order with EU law (the <HT TYPE="ITALIC">Solgar</HT> case<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0007"><P>Judgment of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI></REF.DOC.ECR>).</P></NOTE>). In April 2011 following this Court’s judgment in <HT TYPE="ITALIC">Solgar</HT>, the Conseil d’État (Council of State) judged that, as long as the Commission had not adopted maximum daily doses for vitamins and minerals in food supplements, these could, in principle, be fixed by national law. However, the Conseil d’État (Council of State) partially annulled the Order, specifically in relation to the maximum doses fixed for six vitamins, holding that they were disproportionate.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0008"><P>Vitamins K, B1, B2, B5, B8 and B12. See, CE, <DATE ISO="20110427">27 April 2011</DATE>, <HT TYPE="ITALIC">Solgar Vitamin’s France et autres</HT>, n<HT TYPE="SUP">o</HT>295235; FR:CESSR:2011:295235.20110427.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0020"><NO.P>20.</NO.P><TXT>In the proceedings before the national court leading to the present reference, Noria argues that the Order is incompatible with EU law. The referring court states in its request that it has doubts about the <QUOT.START CODE="2018" REF.END="QE0016" ID="QS0016"/>soundness of the legal element forming the basis for the prosecution<QUOT.END REF.START="QS0016" CODE="2019" ID="QE0016"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0009"><P>The national court does not mention any potential impact on this case of the partial annulment of the Order. That aspect is not considered further here.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0021"><NO.P>21.</NO.P><TXT>In that regard, the referring court notes that the Decree, on the basis of which the Order was adopted, contains a <QUOT.START CODE="2018" REF.END="QE0017" ID="QS0017"/>simplified<QUOT.END REF.START="QS0017" CODE="2019" ID="QE0017"/> mutual recognition procedure<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0010"><P>The order for reference uses the two terms <QUOT.START CODE="2018" REF.END="QE0018" ID="QS0018"/>simplified<QUOT.END REF.START="QS0018" CODE="2019" ID="QE0018"/> (simplifiée) and <QUOT.START CODE="2018" REF.END="QE0019" ID="QS0019"/>streamlined’ (allégée) mutual recognition procedure<QUOT.END REF.START="QS0019" CODE="2019" ID="QE0019"/> interchangeably. I will use <QUOT.START CODE="2018" REF.END="QE0020" ID="QS0020"/>simplified<QUOT.END REF.START="QS0020" CODE="2019" ID="QE0020"/> in this Opinion.</P></NOTE> in the form of the Article 16 evaluation procedure (see above points 12 and 13). That procedure does not, however, apply to food supplements containing vitamins and minerals. The national court states that the absence of a similar procedure for food supplements containing vitamins and minerals amounts to a <QUOT.START CODE="2018" REF.END="QE0021" ID="QS0021"/>derogation from the principle [of mutual recognition]<QUOT.END REF.START="QS0021" CODE="2019" ID="QE0021"/>, which may violate EU law.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0022"><NO.P>22.</NO.P><TXT>The national court also doubts whether the way in which the maximum daily doses were set in the Order complies with the requirements of EU law in terms of adequacy of risk assessment and supporting scientific evidence.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0023"><NO.P>23.</NO.P><TXT>In those circumstances, the Tribunal de grande instance de Perpignan (Regional Court, Perpignan) decided to stay the proceedings and to refer the following questions to the Court for a preliminary ruling:</TXT><P><QUOT.S LEVEL="1"><LIST TYPE="OTHER"><ITEM><NP><NO.P><QUOT.START CODE="2018" REF.END="QE0022" ID="QS0022"/>(1)</NO.P><TXT>Do Directive 2002/46 … and Community principles of free movement of goods and of mutual recognition preclude the laying down of national legislation such as the order of <DATE ISO="20060509">9 May 2006</DATE> which refuses any mutual recognition procedure so far as concerns food supplements based on vitamins and minerals from another Member State by excluding the application of a [simplified] procedure in respect of products lawfully marketed in another Member State that are based on nutrients [whose values exceed the limits set] by the order of <DATE ISO="20060509">9 May 2006</DATE>?</TXT></NP></ITEM><?PAGE NO="6"?><ITEM><NP><NO.P>(2)</NO.P><TXT>Does Directive 2002/46, in particular in Article 5, as well as the principles resulting from Community case-law on the provisions relating to the free movement of goods, permit the maximum daily doses of vitamins and minerals to be set in proportion to the recommended daily allowances by adopting a value equal to three times the recommended daily allowances for nutrients presenting the least risk, a value equal to the recommended daily allowances for nutrients presenting a risk of the upper safe level being exceeded and a value below the recommended daily allowances or even zero for nutrients involving the most risk?</TXT></NP></ITEM><ITEM><NP><NO.P>(3)</NO.P><TXT>Does Directive 2002/46, as well as the principles resulting from Community case-law on the provisions relating to the free movement of goods, permit the doses to be set [in the light of] solely national scientific opinions even though recent international scientific opinions [conclude in favour of] higher doses in identical conditions of use?<QUOT.END REF.START="QS0022" CODE="2019" ID="QE0022"/></TXT></NP></ITEM></LIST></QUOT.S></P></NP.ECR><NP.ECR IDENTIFIER="NP0024"><NO.P>24.</NO.P><TXT>Written observations have been submitted by Noria, the French Government, the EFTA Surveillance Authority (<QUOT.START CODE="2018" REF.END="QE0023" ID="QS0023"/>ESA<QUOT.END REF.START="QS0023" CODE="2019" ID="QE0023"/>) and the European Commission.</TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">IV –</HT></NO.P><TXT><HT TYPE="BOLD">Assessment</HT></TXT></NP></TI></TITLE><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>A –</NO.P><TXT><HT TYPE="ITALIC">Question 1: absence of <QUOT.START CODE="2018" REF.END="QE0024" ID="QS0024"/>simplified mutual recognition procedure<QUOT.END REF.START="QS0024" CODE="2019" ID="QE0024"/></HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0025"><NO.P>25.</NO.P><TXT>Do Articles 34 and 36 TFEU, the principle of free movement of goods and mutual recognition and/or Directive 2002/46 require Member States to foresee <QUOT.START CODE="2018" REF.END="QE0025" ID="QS0025"/>(simplified) mutual recognition procedures<QUOT.END REF.START="QS0025" CODE="2019" ID="QE0025"/><NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0011"><P>The precise meaning of this notion is discussed in detail below at points 37 to 42.</P></NOTE> to allow the marketing on their territory of food supplements containing vitamins and minerals that are lawfully marketed in other Member States? That is the thrust of the referring court’s first question.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0026"><NO.P>26.</NO.P><TXT>For the reasons set out below, I consider that Member States must, in principle, allow marketing on their territory of food supplements containing vitamins and minerals that are lawfully marketed in other Member States. However, such marketing may be refused if that is justified, for example, to safeguard public health. <HT TYPE="ITALIC">Substantively</HT>, any such refusals and accompanying justifications must be based on a <HT TYPE="ITALIC">full risk assessment</HT> based on up-to-date science. <HT TYPE="ITALIC">Procedurally</HT>, exactly how that is achieved is, in principle, left to the Member States.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0027"><NO.P>27.</NO.P><TXT>Before specifically addressing the issue of <QUOT.START CODE="2018" REF.END="QE0026" ID="QS0026"/>mutual recognition procedures<QUOT.END REF.START="QS0026" CODE="2019" ID="QE0026"/> (Section 2 below), I recall the general rule that Member States are free to adopt maximum amounts of vitamins and minerals in food supplements, provided this is justified on the basis of a full risk assessment (Section 1 below).</TXT></NP.ECR><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>1.</NO.P><TXT>Adoption of maxima by Member States</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0028"><NO.P>28.</NO.P><TXT>Article 4(1) of the Directive provides that, for the manufacture of food supplements, only vitamins and minerals listed in Annex I, in the forms listed in Annex II may be used. Article 5(4) of the Directive foresees that the Commission should adopt maximum amounts of vitamins and minerals to be used in foodstuffs. However, it has not yet done so.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0029"><NO.P>29.</NO.P><TXT>In the absence of Commission action in this regard, Member States remain competent to adopt such maxima, while respecting the Treaty rules, including those on the free movement of goods.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0012"><P>Article 11(2) of the Directive; judgment of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0019">19</REF.NP.ECR> to <REF.NP.ECR REF="NP0024">24</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><?PAGE NO="7"?><NP.ECR IDENTIFIER="NP0030"><NO.P>30.</NO.P><TXT>In its judgment in <HT TYPE="ITALIC">Solgar</HT>, the Court confirmed in particular that Member States must comply with Articles 34 and 36 TFEU and <QUOT.START CODE="2018" REF.END="QE0027" ID="QS0027"/>must also be guided by the criteria laid down in Article 5(1) and (2) of [the Directive]<QUOT.END REF.START="QS0027" CODE="2019" ID="QE0027"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0013"><P>Judgment of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0032">32</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> Those criteria are derived from the general requirement to base food law on risk assessment.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0014"><P>Article 6(1) of Regulation (EC) No 178/2002 of the European Parliament and of the Council of <DATE ISO="20020128">28 January 2002</DATE> laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety (<REF.DOC.OJ COLL="L" NO.OJ="031" PAGE.FIRST="1" DATE.PUB="2002">OJ 2002 L 31, p. 1</REF.DOC.OJ>).</P></NOTE> They require that, in fixing maxima, various factors must be taken into account, namely: (i) upper safe levels of vitamins and minerals (<QUOT.START CODE="2018" REF.END="QE0028" ID="QS0028"/>upper safe level<QUOT.END REF.START="QS0028" CODE="2019" ID="QE0028"/>); (ii) intakes from other dietary sources; (iii) reference intakes (together <QUOT.START CODE="2018" REF.END="QE0029" ID="QS0029"/>the Article 5 criteria<QUOT.END REF.START="QS0029" CODE="2019" ID="QE0029"/>).</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0031"><NO.P>31.</NO.P><TXT>It follows from the above that decisions by Member States to impose maxima on use of vitamins and minerals in food supplements must be preceded by a full risk assessment taking into account, in particular, the Article 5 criteria.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0032"><NO.P>32.</NO.P><TXT>There appears to be rather broad agreement in all the written observations submitted to the Court on the points of law set out in the preceding paragraphs. In particular, it is not disputed that Member States have the possibility to adopt acts fixing maxima for use of vitamins and minerals in food supplements, on the basis of a full risk assessment.</TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>2.</NO.P><TXT>Full risk assessment: general and product specific?</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0033"><NO.P>33.</NO.P><TXT>There is, however, a disagreement about whether a full risk assessment of the relevant vitamins and minerals was carried out before adoption of the Order. Nonetheless, that point is not raised by the referring court’s first question. Whether or not a full risk assessment was carried out is for the referring court to verify. I will assume for the moment that a full risk assessment has been carried out (that is the position of the French Government), although I return to the issue in the context of the second and third questions.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0034"><NO.P>34.</NO.P><TXT>More relevant here is the fact that there is a disagreement about whether there needs to be a procedure allowing for some form of additional (simplified) assessment on an individual basis. That is the focus of the first question.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0035"><NO.P>35.</NO.P><TXT>In response to this, the French Government and the ESA argue in substance that, once a full risk assessment has been carried out and maxima fixed in national legislation, those maxima can be used to prevent imports. EU law does not require a specific procedure allowing for assessment of individual products which are acknowledged as exceeding the maxima.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0036"><NO.P>36.</NO.P><TXT>By contrast, Noria and the Commission argue that, regardless of the existence of generally applicable maxima in national legislation, a procedure must exist whereby an importer can request authorisation to market its products in that Member State even if they exceed those maxima.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0037"><NO.P>37.</NO.P><TXT>Does EU law require such a <QUOT.START CODE="2018" REF.END="QE0030" ID="QS0030"/>simplified mutual recognition procedure<QUOT.END REF.START="QS0030" CODE="2019" ID="QE0030"/>?<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0015"><P>In the <HT TYPE="ITALIC">Solgar</HT> case, it was argued that the Order was incompatible with EU law due to the absence of a mutual recognition procedure. However, that aspect was not addressed in the national court’s request (see Opinion of Advocate General Jääskinen in <REF.DOC.ECR><NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2009:795">EU:C:2009:795</NO.ECLI>, points <REF.NP.ECR REF="NP0028">28</REF.NP.ECR> and <REF.NP.ECR REF="NP0029">29</REF.NP.ECR></REF.DOC.ECR>)) or the Court’s judgment.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0038"><NO.P>38.</NO.P><TXT>The Directive does not refer to or define such a requirement. Nor do I see any scope for inferring such a procedural requirement from the Directive. Can such a requirement be deduced from Articles 34 and 36 TFEU and the principle of free movement of goods and mutual recognition? Crucial to the answer is the meaning of the term <QUOT.START CODE="2018" REF.END="QE0031" ID="QS0031"/>(simplified) mutual recognition procedure<QUOT.END REF.START="QS0031" CODE="2019" ID="QE0031"/>.</TXT></NP.ECR><?PAGE NO="8"?><NP.ECR IDENTIFIER="NP0039"><NO.P>39.</NO.P><TXT>The principle of mutual recognition is derived from the prohibition of quantitative restrictions on imports between Member States and measures having an equivalent effect thereto, set out in Article 34 TFEU.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0016"><P>See, for example, judgment of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑24/00</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:70">EU:C:2004:70</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0021">21</REF.NP.ECR> and <REF.NP.ECR REF="NP0022">22</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> According to that principle, if a product has been lawfully manufactured and/or marketed in one Member State, then other Member States must as a general rule accept importation of that product into their territory.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0017"><P>Judgment of <REF.DOC.ECR><DATE ISO="19790220">20 February 1979</DATE>, <NAME.CASE><HT TYPE="ITALIC">Rewe-Zentral</HT></NAME.CASE> (<NO.CASE>120/78</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1979:42">EU:C:1979:42</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0014">14</REF.NP.ECR> and <REF.NP.ECR REF="NP0015">15</REF.NP.ECR></REF.DOC.ECR>). See also judgments of <REF.DOC.ECR><DATE ISO="19810617">17 June 1981</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Ireland</HT></NAME.CASE>, (<NO.CASE>C‑113/80</NO.CASE>; <NO.ECLI ECLI="ECLI:EU:C:1981:139">EU:C:1981:139</NO.ECLI></REF.DOC.ECR>), and of <REF.DOC.ECR><DATE ISO="20090210">10 February 2009</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Italy</HT></NAME.CASE>, (<NO.CASE>C‑110/05</NO.CASE>; <NO.ECLI ECLI="ECLI:EU:C:2009:66">EU:C:2009:66</NO.ECLI></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0040"><NO.P>40.</NO.P><TXT>The prohibition on restrictions on the free movement of goods is not, however, absolute. Member States can still justify refusals to allow importation of products lawfully produced or marketed in other Member States. That can be done, for example, to safeguard public health, subject to the requirements of necessity and proportionality.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0018"><P>See, for example, in relation to restrictions on inclusion of vitamins in foodstuffs, judgments of <REF.DOC.ECR><DATE ISO="20030923">23 September 2003</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Denmark</HT></NAME.CASE> (<NO.CASE>C‑192/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2003:492">EU:C:2003:492</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0042">42</REF.NP.ECR> and <REF.NP.ECR REF="NP0043">43</REF.NP.ECR></REF.DOC.ECR>); of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑24/00</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:70">EU:C:2004:70</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0049">49</REF.NP.ECR> and <REF.NP.ECR REF="NP0050">50</REF.NP.ECR></REF.DOC.ECR>); of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Greenham and Abel</HT></NAME.CASE> (<NO.CASE>C‑95/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:71">EU:C:2004:71</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0037">37</REF.NP.ECR> and <REF.NP.ECR REF="NP0038">38</REF.NP.ECR></REF.DOC.ECR>); and of <REF.DOC.ECR><DATE ISO="19830714">14 July 1983</DATE>, <NAME.CASE><HT TYPE="ITALIC">Sandoz</HT></NAME.CASE> (<NO.CASE>174/82</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1983:213">EU:C:1983:213</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0016">16</REF.NP.ECR> and <REF.NP.ECR REF="NP0017">17</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0041"><NO.P>41.</NO.P><TXT>It follows that a <QUOT.START CODE="2018" REF.END="QE0032" ID="QS0032"/>mutual recognition procedure<QUOT.END REF.START="QS0032" CODE="2019" ID="QE0032"/> in this context is not a procedure that would require Member States to recognise automatically and authorise import of any food supplement produced or marketed legally in other Member States. Member States must have the opportunity to verify the absence of genuine risks for public health and refuse imports, if such risks are indeed considered to exist.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0019"><P>See, in this sense in relation to processing aids, judgment of <REF.DOC.ECR><DATE ISO="20100128">28 January 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑333/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:44">EU:C:2010:44</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0109">109</REF.NP.ECR></REF.DOC.ECR>), where such a requirement is referred to as a <QUOT.START CODE="2018" REF.END="QE0033" ID="QS0033"/>mutual recognition clause<QUOT.END REF.START="QS0033" CODE="2019" ID="QE0033"/>.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0042"><NO.P>42.</NO.P><TXT>A <QUOT.START CODE="2018" REF.END="QE0034" ID="QS0034"/>mutual recognition procedure<QUOT.END REF.START="QS0034" CODE="2019" ID="QE0034"/> would then be a procedure whereby a Member State basically verifies if there is a genuine risk for public health <HT TYPE="ITALIC">and hence whether or not it has a valid justification for refusing importation</HT>. If no such risk and no valid justification exist, the importation cannot be legitimately prevented.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0020"><P>The adjective <QUOT.START CODE="2018" REF.END="QE0035" ID="QS0035"/>simplified<QUOT.END REF.START="QS0035" CODE="2019" ID="QE0035"/> (or <QUOT.START CODE="2018" REF.END="QE0036" ID="QS0036"/>streamlined<QUOT.END REF.START="QS0036" CODE="2019" ID="QE0036"/>) implies something not too time consuming or complex. I will focus here on the basic expression <QUOT.START CODE="2018" REF.END="QE0037" ID="QS0037"/>mutual recognition procedure<QUOT.END REF.START="QS0037" CODE="2019" ID="QE0037"/>.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0043"><NO.P>43.</NO.P><TXT>But what happens if the risk already appears to have been fully researched and the justification fully developed? In the present case, that is the contention. The French Government effectively argues that it has justified its requirements relating to <HT TYPE="ITALIC">specific nutrients</HT> on the basis of a <HT TYPE="ITALIC">full risk assessment</HT> complying with EU law requirements in terms of thoroughness and consideration of specific factors.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0044"><NO.P>44.</NO.P><TXT>Given those circumstances, what precise purpose would a mutual recognition procedure practically serve? What concrete steps would it require a Member State to take?</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0045"><NO.P>45.</NO.P><TXT>Would it be to repeat the same assessment of the same nutrient(s) as has already been conducted?<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0021"><P>The national court refers to the Article 16 evaluation procedure, which exists for various <HT TYPE="ITALIC">other</HT> substances in food supplements (see above points 10 to 12). In that procedure, the importer provides data for the evaluation of the relevant substance. The competent national authority must assess the dossier and may justify refusal on public health grounds. To the extent that the French authorities have already taken into account all such data in their original risk assessment, an application of the Article 16 evaluation procedure here would simply involve repeating that assessment.</P></NOTE> If that is indeed what is being suggested, then the answer is, in my view, a clear no.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0046"><NO.P>46.</NO.P><TXT>If a Member State has complied with EU law requirements in terms of a full risk assessment of a nutrient, and has adopted generally applicable maxima on that basis, neither Article 34 TFEU nor the principles of free movement or mutual recognition require it to revise that conclusion simply because an individual importer does not like the result. On the other hand, it ought to be added that the EU law principle of effective judicial protection requires that the original act imposing generally applicable maxima must of course be open to judicial review under (primarily) national procedural rules.</TXT></NP.ECR><?PAGE NO="9"?><NP.ECR IDENTIFIER="NP0047"><NO.P>47.</NO.P><TXT>In their submissions, both Noria and the Commission refer to the Court’s case-law on prior authorisations to support the argument that Member States must foresee simplified procedures for allowing commercialisation of imported products.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0048"><NO.P>48.</NO.P><TXT>According to that case-law, where a Member State requires prior authorisation, the authorisation procedure must respect minimum requirements. Thus, it must be <QUOT.START CODE="2018" REF.END="QE0038" ID="QS0038"/>readily accessible and can be completed within a reasonable time, and, if it leads to a refusal, the decision of refusal must be open to challenge before the courts<QUOT.END REF.START="QS0038" CODE="2019" ID="QE0038"/>. A refusal can be made <QUOT.START CODE="2018" REF.END="QE0039" ID="QS0039"/>only if such substance poses a genuine risk to public health<QUOT.END REF.START="QS0039" CODE="2019" ID="QE0039"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0022"><P>See judgment of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑24/00</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:70">EU:C:2004:70</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0026">26</REF.NP.ECR>, <REF.NP.ECR REF="NP0027">27</REF.NP.ECR> and <REF.NP.ECR REF="NP0036">36</REF.NP.ECR></REF.DOC.ECR>). See also judgments of <REF.DOC.ECR><DATE ISO="19920716">16 July 1992</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑344/90</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1992:328">EU:C:1992:328</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0009">9</REF.NP.ECR> and <REF.NP.ECR REF="NP0010">10</REF.NP.ECR></REF.DOC.ECR>); of <REF.DOC.ECR><DATE ISO="20030923">23 September 2003</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Denmark</HT></NAME.CASE> (<NO.CASE>C‑192/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2003:492">EU:C:2003:492</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0046">46</REF.NP.ECR></REF.DOC.ECR>); and of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Greenham and Abel</HT></NAME.CASE> (<NO.CASE>C‑95/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:71">EU:C:2004:71</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0035">35</REF.NP.ECR> and <REF.NP.ECR REF="NP0036">36</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0049"><NO.P>49.</NO.P><TXT>However, those cases are very different from the present one. They focused on situations where Member States required importers to obtain authorisation before marketing their product <HT TYPE="ITALIC">apparently without having first conducted a full risk assessment that would justify eventual prohibition</HT>. The Court required in such cases that importers were able to trigger a procedure that would involve proper consideration by Member States of the justifications for any restrictions. That procedure had to be effective and the decisions appealable.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0050"><NO.P>50.</NO.P><TXT>The Court had taken a similar approach in earlier cases involving <HT TYPE="ITALIC">broad prohibitions on use of additives not based on a full risk assessment</HT>. Again in those cases, the Court has required the possibility for importers to request authorisation, and such requests can only be rejected after a full risk assessment.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0023"><P>See, for example, judgments of <REF.DOC.ECR><DATE ISO="19860506">6 May 1986</DATE>, <NAME.CASE><HT TYPE="ITALIC">Muller and Others</HT></NAME.CASE> (<NO.CASE>304/84</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1986:194">EU:C:1986:194</NO.ECLI>, in particular paragraphs <REF.NP.ECR REF="NP0024">24</REF.NP.ECR> and <REF.NP.ECR REF="NP0026">26</REF.NP.ECR></REF.DOC.ECR>); and of <REF.DOC.ECR><DATE ISO="19870312">12 March 1987</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Greece</HT></NAME.CASE> (<NO.CASE>176/84</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1987:125">EU:C:1987:125</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0039">39</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0051"><NO.P>51.</NO.P><TXT>However, those situations are completely different from ones where a detailed assessment of the public health justification for a particular restriction has <HT TYPE="ITALIC">already</HT> been carried out, and complies with the requirements of EU law in terms of scientific rigour.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0052"><NO.P>52.</NO.P><TXT>In the <QUOT.START CODE="2018" REF.END="QE0040" ID="QS0040"/>prior authorisation cases<QUOT.END REF.START="QS0040" CODE="2019" ID="QE0040"/> and <QUOT.START CODE="2018" REF.END="QE0041" ID="QS0041"/>broad prohibition<QUOT.END REF.START="QS0041" CODE="2019" ID="QE0041"/> cases referred to above, the fundamental issue was not whether (or not) Member States foresaw specific procedural solutions national law, but rather that they ultimately had to base their restrictions on science.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0053"><NO.P>53.</NO.P><TXT>Once a scientific risk assessment has been carried out, EU law does not require Member States to invent procedures providing for a repetition of that assessment, on the basis of the same evidence.</TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>3.</NO.P><TXT>New evidence and fresh assessments</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0054"><NO.P>54.</NO.P><TXT>The above analysis assumes that the <QUOT.START CODE="2018" REF.END="QE0042" ID="QS0042"/>mutual recognition procedure<QUOT.END REF.START="QS0042" CODE="2019" ID="QE0042"/> involves the Member State basically being asked to reread the same file to see if it comes to a different result. I do not consider that such an exercise is required by EU law.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0055"><NO.P>55.</NO.P><TXT>The answer could, of course, be different if the Member State <HT TYPE="ITALIC">were indeed being asked to do something different</HT>. Whether such differences existed in the present case is a question of fact, to be ascertained by the national court. However, one specific possibility is worth highlighting here.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0056"><NO.P>56.</NO.P><TXT>In my view, importers must certainly be able to present <HT TYPE="ITALIC">new scientific evidence</HT> that could lead to a reconsideration of the original restrictions. By <QUOT.START CODE="2018" REF.END="QE0043" ID="QS0043"/>new scientific evidence<QUOT.END REF.START="QS0043" CODE="2019" ID="QE0043"/> I understand evidence post-dating the restrictions or otherwise not taken into account in the original assessment. Member States must give that evidence due consideration.</TXT></NP.ECR><?PAGE NO="10"?><NP.ECR IDENTIFIER="NP0057"><NO.P>57.</NO.P><TXT>I would not describe that as a <QUOT.START CODE="2018" REF.END="QE0044" ID="QS0044"/>mutual recognition procedure<QUOT.END REF.START="QS0044" CODE="2019" ID="QE0044"/>. It appears to me rather more akin to a standard form of a new, fresh administrative review, commonly present in the national systems of administrative procedure: new facts came to light, which made the previously adopted administrative decision difficult to maintain for the future. Nonetheless, whatever such a procedure is called, a possibility must exist for importers to submit new evidence.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0024"><P>This can be contrasted, for example, with a broad prohibition accompanied by a prior authorisation system where it is rather clear that a full review of existing evidence has not been conducted. See, in this sense, judgment of <REF.DOC.ECR><DATE ISO="19920716">16 July 1992</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑344/90</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1992:328">EU:C:1992:328</NO.ECLI></REF.DOC.ECR>) at paragraph 7: this confirms a positive scientific assessment of the relevant substance but goes on to accept the national prohibition, subject to efficient authorisation procedures. See also paragraphs 13 to 15 of that judgment.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0058"><NO.P>58.</NO.P><TXT>The existence of such a requirement is confirmed by several factors. Food law must be based on a full scientific risk analysis.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0025"><P>Article 6(1) of Regulation No 178/2002.</P></NOTE> That requirement, in itself, clearly implies up-to-date science. I do not think that that expression could be read as meaning a full albeit outdated scientific risk assessment. That conclusion is, moreover, supported by references in the case-law to assessments on the basis of <QUOT.START CODE="2018" REF.END="QE0045" ID="QS0045"/>the most recent results<QUOT.END REF.START="QS0045" CODE="2019" ID="QE0045"/> of scientific research.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0026"><P>See, for example, judgment of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0069">69</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> Systemically, it is also confirmed by the existence in the Directive (as well as many other EU law acts) of mechanisms and procedures designed to ensure new scientific research is taken into consideration.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0027"><P>Article 12 of the Directive; Article 22 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council of <DATE ISO="20061218">18 December 2006</DATE> concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (<REF.DOC.OJ COLL="L" NO.OJ="396" PAGE.FIRST="1" DATE.PUB="2006">OJ 2006 L 396, p. 1</REF.DOC.OJ>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0059"><NO.P>59.</NO.P><TXT>Procedurally speaking, exactly how the requirement to consider new scientific evidence is fulfilled is a matter for Member States. However, in doing so, Member States must ensure that those procedures are effective. In that regard, the minimum conditions already well established by the Court in relation to prior authorisation systems for nutrients in food supplements and referred to above can, in my view, be applied <HT TYPE="ITALIC">mutatis mutandis</HT>. Thus, Member States must ensure that the procedure for assessing new scientific evidence is readily accessible, can be completed within a reasonable time,<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0028"><P>That does not imply any specific time frame. If there is indeed new evidence, Member States are expected to act with celerity but they must also have sufficient time to give due consideration to that evidence.</P></NOTE> and if it leads to refusal must be open to challenge before the courts.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0029"><P>See above points 48 and 49.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0060"><NO.P>60.</NO.P><TXT>It is up to the national court to determine whether, in this case, Noria was in a position to present such new evidence but was unable to do so effectively in the way outlined above.</TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>4.</NO.P><TXT>Conclusion on the first question</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0061"><NO.P>61.</NO.P><TXT>In the light of the above, I propose to reply to the national court’s first question as follows:</TXT><P>Article 34 TFEU and the principle of mutual recognition preclude a national rule, which prohibits importation of food supplements lawfully produced or marketed in another Member State, on the basis that those food supplements contain a nutrient in quantities exceeding a given maximum, where such maximum has been fixed without a prior scientific risk assessment guided by the criteria laid down in Article 5(1) and (2) of Directive 2002/46. Article 34 TFEU and the principle of mutual recognition require Member States to ensure that importers may seek revision of that prior risk assessment on the basis of scientific evidence not previously taken into account by the Member State. Procedures for reviewing such new scientific evidence must be readily accessible, completed within a reasonable time and the resulting decisions must be open to challenge before national courts.</P></NP.ECR></GR.SEQ><?PAGE NO="11"?><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>5.</NO.P><TXT>Post scriptum on Regulation No 764/2008</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0062"><NO.P>62.</NO.P><TXT>Neither the national court nor any of the parties have referred to Regulation (EC) No 764/2008,<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0030"><P>Regulation of the European Parliament and of the Council of <DATE ISO="20080709">9 July 2008</DATE> laying down procedures relating to the application of certain national technical rules to products lawfully marketed in another Member State and repealing Decision No 3052/95/EC (<REF.DOC.OJ COLL="L" NO.OJ="218" PAGE.FIRST="21" DATE.PUB="2008">OJ 2008 L 218, p. 21</REF.DOC.OJ>).</P></NOTE> also known as the <QUOT.START CODE="2018" REF.END="QE0046" ID="QS0046"/>mutual recognition regulation<QUOT.END REF.START="QS0046" CODE="2019" ID="QE0046"/> (<QUOT.START CODE="2018" REF.END="QE0047" ID="QS0047"/>the Regulation<QUOT.END REF.START="QS0047" CODE="2019" ID="QE0047"/>). For that reason, I assume it is not an issue in the main proceedings and will not consider it in detail.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0063"><NO.P>63.</NO.P><TXT>Nonetheless, the Regulation does at least present some interest from a systemic point of view as the Commission has in the past stated that it applies to decisions based on national rules fixing maximum amounts of nutrients in food supplements.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0031"><P>European Commission Enterprise and Industry Directorate-General Guidance document, <QUOT.START CODE="2018" REF.END="QE0048" ID="QS0048"/>The application of the Mutual Recognition Regulation to food supplements<QUOT.END REF.START="QS0048" CODE="2019" ID="QE0048"/>, Brussels, <DATE ISO="20100201">1.2.2010</DATE>, at point 4.2.</P></NOTE> Seen from this perspective, the Regulation confirms the general approach to the first question presented in this section.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0064"><NO.P>64.</NO.P><TXT>Under the Regulation, one of the actions that must be taken by a Member State intending to adopt a decision prohibiting importation of products lawfully manufactured or sold in other Member States is to inform the operator concerned of the (public health) justifications for refusal, setting out supporting scientific evidence and allowing the operator to comment (see Article 6).</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0065"><NO.P>65.</NO.P><TXT>Thus, EU secondary law, in codifying what could be described as a <QUOT.START CODE="2018" REF.END="QE0049" ID="QS0049"/>mutual recognition procedure<QUOT.END REF.START="QS0049" CODE="2019" ID="QE0049"/>, aspires to impose rather limited procedural requirements on Member States. Effectively, if a decision to refuse importation is made, it must be reasoned and the operator must have had a chance to submit comments. The Regulation does not require a rerun of already executed risk assessments. It does not explicitly impose any time limit for the final decision. There is no obligation to foresee a specific provision in national law setting out the procedure.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0066"><NO.P>66.</NO.P><TXT>To that extent, I consider that the Regulation provides further support that primary EU free movement law and the general principle of mutual recognition cannot in themselves impose detailed procedural requirements on Member States, in terms of adoption of specific mutual recognition provisions or procedures for <QUOT.START CODE="2018" REF.END="QE0050" ID="QS0050"/>repeat reviews<QUOT.END REF.START="QS0050" CODE="2019" ID="QE0050"/> of scientific evidence. National law must, however, comply with the general requirements set out above in relation to the original assessment and allow for updating of that assessment on the basis of new scientific evidence (see point 56).</TXT></NP.ECR></GR.SEQ></GR.SEQ><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>B –</NO.P><TXT><HT TYPE="ITALIC">Question 2</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0067"><NO.P>67.</NO.P><TXT>By its second question, the national court asks whether maximum daily doses of vitamins and minerals can be set in proportion to recommended daily allowances, basically as multiples of reference intakes.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0032"><P>As referred to in Article 5 of the Directive.</P></NOTE> The national court also asks whether vitamins and minerals can be grouped for that purpose depending on level of risk they present, for example, for all low-risk nutrients, the maximum is set at three times the reference intake.</TXT></NP.ECR><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>1.</NO.P><TXT>However results are presented, a full risk assessment is required</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0068"><NO.P>68.</NO.P><TXT>It is useful to distinguish at the outset between presentation and substance.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0069"><NO.P>69.</NO.P><TXT>As set out above at point 29, Member States are free to set maximum amounts of vitamins and minerals in food supplements, until the Commission does so.</TXT></NP.ECR><?PAGE NO="12"?><NP.ECR IDENTIFIER="NP0070"><NO.P>70.</NO.P><TXT>The real question of <HT TYPE="ITALIC">substance</HT> is whether a full risk assessment has been conducted on a case-by-case basis and taking into account, in particular, the Article 5 criteria.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0033"><P><QUOT.START CODE="2018" REF.END="QE0051" ID="QS0051"/>Case-by-case<QUOT.END REF.START="QS0051" CODE="2019" ID="QE0051"/> should, in principle, be read as <QUOT.START CODE="2018" REF.END="QE0052" ID="QS0052"/>nutrient-by-nutrient<QUOT.END REF.START="QS0052" CODE="2019" ID="QE0052"/> since restrictions must be based on real risk. However, it cannot be excluded that there is some justification for grouping nutrients for the purposes of scientific evaluation. See, on that point, judgment of <REF.DOC.ECR><DATE ISO="20040429">29 April 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Germany</HT></NAME.CASE> (<NO.CASE>C‑387/99</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:235">EU:C:2004:235</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0079">79</REF.NP.ECR> and <REF.NP.ECR REF="NP0082">82</REF.NP.ECR></REF.DOC.ECR>), which envisages the grouping of substances in this way. See also my Opinion in <REF.DOC.ECR><NAME.CASE><HT TYPE="ITALIC">Queisser Pharma</HT></NAME.CASE> (<NO.CASE>C‑282/15</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2016:589">EU:C:2016:589</NO.ECLI></REF.DOC.ECR>) at point 83.</P></NOTE> As long as that has been done, EU law does not contain specific rules on the way in which those maxima must be <HT TYPE="ITALIC">presented</HT>.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0071"><NO.P>71.</NO.P><TXT>There is no requirement that maxima be presented nutrient by nutrient. There is no requirement that maxima be presented as absolute amounts (for example, in mg) as opposed to multiples of recommended daily allowances.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0072"><NO.P>72.</NO.P><TXT>In replying to this question, Noria and the ESA basically argue that a full scientific assessment has not been carried out, and the way the maxima are presented proves (or at least confirms) that point.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0073"><NO.P>73.</NO.P><TXT>Whether or not such a full scientific assessment has been carried out and how that is proven are questions of fact and evidentiary rules for the national court to resolve. However, I do not consider that the choice of a particular method of presentation can <HT TYPE="ITALIC">in itself</HT> constitute irrefutable proof that a full assessment was or was not carried out.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0074"><NO.P>74.</NO.P><TXT>This conclusion is, moreover, clearly supported by the Court’s judgment in <HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Germany</HT>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0034"><P>Judgment of <REF.DOC.ECR><DATE ISO="20040429">29 April 2004</DATE>, <NO.CASE>C‑387/99</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:235">EU:C:2004:235</NO.ECLI></REF.DOC.ECR>.</P></NOTE> In that judgment the Commission contested a German rule which automatically classified products that contained three times the recommended daily dose of vitamins (the rule applied to a range of vitamins) as medicinal products. The Court condemned what it referred to as the <QUOT.START CODE="2018" REF.END="QE0053" ID="QS0053"/>triple amount rule<QUOT.END REF.START="QS0053" CODE="2019" ID="QE0053"/>, because it was not preceded by a pharmacological evaluation of each vitamin or group of vitamins. In doing so, the Court acknowledged that the evaluation <QUOT.START CODE="2018" REF.END="QE0054" ID="QS0054"/>may correctly lead to the same result<QUOT.END REF.START="QS0054" CODE="2019" ID="QE0054"/>. However, the reality was that such a case-by-case analysis had not been conducted.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0035"><P>Judgment of <REF.DOC.ECR><DATE ISO="20040429">29 April 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Germany</HT></NAME.CASE> (<NO.CASE>C‑387/99</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:235">EU:C:2004:235</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0081">81</REF.NP.ECR> and <REF.NP.ECR REF="NP0082">82</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>2.</NO.P><TXT>Observations on the adequacy of the risk assessment</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0075"><NO.P>75.</NO.P><TXT>I would add the following observations concerning the adequacy of the risk assessment.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0076"><NO.P>76.</NO.P><TXT>First, as mentioned above, the risk assessment must, in principle, be carried out on a nutrient-by-nutrient basis. Some form of common assessment cannot be completely excluded, but would have to be duly justified.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0036"><P>See above, footnote 32.</P></NOTE> In their observations, the French Government confirmed that the maxima were fixed on the basis of scientific opinions of the relevant French body, and annexed copies of those. I note that those opinions appear to cover some but not all nutrients for which maxima have been fixed and which appear in the Noria products (on the basis of the product descriptions contained in Noria’s observations).</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0077"><NO.P>77.</NO.P><TXT>Second, the risk assessment must be based on data of a certain quality. For example, Article 5 of the Directive refers to <QUOT.START CODE="2018" REF.END="QE0055" ID="QS0055"/>generally accepted scientific data<QUOT.END REF.START="QS0055" CODE="2019" ID="QE0055"/>. What this implies, in particular whether there is a need to refer to international scientific research, is further discussed under question 3.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0078"><NO.P>78.</NO.P><TXT>Third, Noria, the Commission and the ESA’s observations on these questions refer to one of the Article 5 criteria in particular, namely the upper safe level. It is unclear whether upper safe levels were ever fixed for all the nutrients concerned.</TXT></NP.ECR><?PAGE NO="13"?><NP.ECR IDENTIFIER="NP0079"><NO.P>79.</NO.P><TXT>Whether those levels have actually been fixed is a question of fact for the national court. It is the case that those levels constitute one of the Article 5 criteria and as such must, in principle, be taken into account in the fixing of maxima.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0037"><P>Judgment of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0066">66</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0080"><NO.P>80.</NO.P><TXT>That said, even where upper safe levels have <HT TYPE="ITALIC">not</HT> been established, it may still be possible for Member States to invoke the precautionary principle to justify protective measures. Thus, as confirmed by the Court in <HT TYPE="ITALIC">Solgar</HT>, if <QUOT.START CODE="2018" REF.END="QE0056" ID="QS0056"/>scientific uncertainty persists as regards the existence or extent of real risks to human health … Member State may, in accordance with the precautionary principle, take protective measures without having to wait until the reality and seriousness of those risks are fully demonstrated. However, the risk assessment cannot be based on purely hypothetical considerations<QUOT.END REF.START="QS0056" CODE="2019" ID="QE0056"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0038"><P>Judgment of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0067">67</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE></TXT></NP.ECR></GR.SEQ><GR.SEQ LEVEL="3"><TITLE><TI><NP><NO.P>3.</NO.P><TXT>Conclusion</TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0081"><NO.P>81.</NO.P><TXT>In the light of the above, I propose to reply to the national court’s second question as follows:</TXT><P>Article 34 TFEU and the principle of mutual recognition preclude a national rule, which prohibits importation of food supplements lawfully produced or marketed in another Member State, on the basis that those food supplements contain a nutrient in quantities exceeding a given maximum, where such maximum has been fixed without a prior scientific risk assessment guided by the criteria laid down in Article 5(1) and (2) of Directive 2002/46. Where such a prior risk assessment has been conducted, the aforementioned principles and provisions of EU law do not prevent presentation of resulting maxima either (a) by group of two or more nutrients or (b) as multiples of reference intakes.</P></NP.ECR></GR.SEQ></GR.SEQ><GR.SEQ LEVEL="2"><TITLE><TI><NP><NO.P>C –</NO.P><TXT><HT TYPE="ITALIC">Question 3</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0082"><NO.P>82.</NO.P><TXT>By its third question the national court asked whether maximum doses for nutrients in food supplements can be set on the basis of national scientific opinion alone. The national court is specifically concerned with situations where international scientific opinion foresees safe maxima that are higher than those proposed by national scientific opinion.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0083"><NO.P>83.</NO.P><TXT>For the reasons developed below, I consider that maximum doses for nutrients in food supplements must be set taking into account the most <HT TYPE="ITALIC">relevant</HT> and <HT TYPE="ITALIC">recent</HT> scientific evidence, whether that is national or international only or includes both. Member States are not required to automatically align maxima set under national law with those referred to in international opinion, simply because the latter are higher than those referred to in national opinion. If relevant and in particular contradictory international scientific evidence exists, however, it cannot be ignored: Member States are obliged to take it into account when making their own assessment and explain why they decided to adopt a different approach.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0084"><NO.P>84.</NO.P><TXT>No applicable EU law act specifies clearly whether sources of scientific evidence used when setting maximum amounts of vitamins and minerals present in food supplements can be national only or must imperatively include international opinion.</TXT></NP.ECR><?PAGE NO="14"?><NP.ECR IDENTIFIER="NP0085"><NO.P>85.</NO.P><TXT>The only potentially relevant reference in the Directive appears in Article 5 and recital 14,<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0039"><P>As explained above at points 30 and 31 of this Opinion, according to existing case-law, in setting maxima Member States must be <QUOT.START CODE="2018" REF.END="QE0057" ID="QS0057"/>guided<QUOT.END REF.START="QS0057" CODE="2019" ID="QE0057"/> by the criteria laid down in Article 5 of the Directive.</P></NOTE> which requires upper safe levels to be established by <QUOT.START CODE="2018" REF.END="QE0058" ID="QS0058"/>scientific risk assessment based on <HT TYPE="ITALIC">generally accepted scientific data</HT><QUOT.END REF.START="QS0058" CODE="2019" ID="QE0058"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0040"><P>Case-law requires Member States to be <QUOT.START CODE="2018" REF.END="QE0059" ID="QS0059"/>guided<QUOT.END REF.START="QS0059" CODE="2019" ID="QE0059"/> by the Article 5 criteria when setting the maximum levels of nutrients in food supplements (see above, point 30). The Directive does not, strictly speaking, apply directly in such cases. Nonetheless, it must clearly be central to any systemic understanding of the evidence Member States should take into account when setting such maxima.</P></NOTE> It does not state whether the <QUOT.START CODE="2018" REF.END="QE0060" ID="QS0060"/>generally accepted scientific data<QUOT.END REF.START="QS0060" CODE="2019" ID="QE0060"/> must be national or international.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0086"><NO.P>86.</NO.P><TXT>Regulation No 178/2002 (the General Food Regulation) does not explicitly require risk assessments to be based on international scientific data either. Article 6(2) and recital 18 of the General Food Regulation provide that <QUOT.START CODE="2018" REF.END="QE0061" ID="QS0061"/>risk assessment shall be based on the <HT TYPE="ITALIC">available scientific evidence</HT> and undertaken in an independent, objective and transparent manner<QUOT.END REF.START="QS0061" CODE="2019" ID="QE0061"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0041"><P>Emphasis added.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0087"><NO.P>87.</NO.P><TXT>The case-law of the Court requires that, when setting maximum amounts of vitamins and minerals, Member States must undertake a scientific assessment of the risks to human health which is based on the relevant scientific data and not on purely hypothetical considerations.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0042"><P>See, for example, judgment of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0065">65</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> It also refers to <QUOT.START CODE="2018" REF.END="QE0062" ID="QS0062"/>comprehensive assessment of the risk for health based on the most reliable scientific data available and the most recent results of international research<QUOT.END REF.START="QS0062" CODE="2019" ID="QE0062"/>.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0043"><P>Judgments of <REF.DOC.ECR><DATE ISO="20100429">29 April 2010</DATE>, <NAME.CASE><HT TYPE="ITALIC">Solgar and Others</HT></NAME.CASE> (<NO.CASE>C‑446/08</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2010:233">EU:C:2010:233</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0069">69</REF.NP.ECR></REF.DOC.ECR>); of <REF.DOC.ECR><DATE ISO="20030923">23 September 2003</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Denmark</HT></NAME.CASE> (<NO.CASE>C‑192/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2003:492">EU:C:2003:492</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0051">51</REF.NP.ECR></REF.DOC.ECR>); of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑24/00</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:70">EU:C:2004:70</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0053">53</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> The Court’s case-law does, therefore, arguably constitute a basis for saying that maxima must be based on <HT TYPE="ITALIC">international</HT> scientific opinion.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0088"><NO.P>88.</NO.P><TXT>However, I do not consider that this should be read as an absolute requirement, amounting to a <HT TYPE="ITALIC">de facto</HT> obligation of quoting international scientific opinion. This follows partly from the fact that no such requirement appears in detailed secondary legislation (in particular the General Food Regulation) and the fact that case-law descriptions of the data, references and/or evidence that must be taken into account are not consistent in this regard.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0044"><P>See, for example, judgment of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Greenham and Abel</HT></NAME.CASE> (<NO.CASE>C‑95/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:71">EU:C:2004:71</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0042">42</REF.NP.ECR></REF.DOC.ECR>) referring to <QUOT.START CODE="2018" REF.END="QE0063" ID="QS0063"/>the results of international scientific research<QUOT.END REF.START="QS0063" CODE="2019" ID="QE0063"/> (paragraph 40); <QUOT.START CODE="2018" REF.END="QE0064" ID="QS0064"/>the most reliable scientific data available and the most recent results of international research<QUOT.END REF.START="QS0064" CODE="2019" ID="QE0064"/> (paragraph 47); or simply to the <QUOT.START CODE="2018" REF.END="QE0065" ID="QS0065"/>latest scientific data<QUOT.END REF.START="QS0065" CODE="2019" ID="QE0065"/> (paragraph 42). In earlier cases the Court has been more specific, referring to international research and citing the work of various clearly identified bodies (judgment of <REF.DOC.ECR><DATE ISO="19870312">12 March 1987</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Greece</HT></NAME.CASE> (<NO.CASE>C‑176/84</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1987:125">EU:C:1987:125</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0038">38</REF.NP.ECR> and <REF.NP.ECR REF="NP0045">45</REF.NP.ECR></REF.DOC.ECR>); see also judgment of <REF.DOC.ECR><DATE ISO="19860506">6 May 1986</DATE>, <NAME.CASE><HT TYPE="ITALIC">Muller and Others</HT></NAME.CASE> (<NO.CASE>304/84</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1986:194">EU:C:1986:194</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0024">24</REF.NP.ECR></REF.DOC.ECR>). Such specifications have not been repeated in such detail in later judgments.</P></NOTE> More importantly, it is rather clear from a broader reading of the case-law that the fundamental concern is not about the details of bibliographies. It is rather that restrictions are justified on the basis of solid science demonstrating real risk or at least the inability to exclude risk, which results from a lack of science. That approach stands in contrast to restrictions based on outdated or partial assessments, or hypothetical risks.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0045"><P>See judgment of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑24/00</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:70">EU:C:2004:70</NO.ECLI>, paragraph <REF.NP.ECR REF="NP0071">71</REF.NP.ECR></REF.DOC.ECR>) for an example of a case where the Commission’s claim that no health risk had been demonstrated was considered as not established on the basis of an opinion from a French national scientific committee. It is, however, unclear whether that opinion itself referred to international research (see footnote 46 below on the notion of <QUOT.START CODE="2018" REF.END="QE0066" ID="QS0066"/>international opinion<QUOT.END REF.START="QS0066" CODE="2019" ID="QE0066"/>).</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0089"><NO.P>89.</NO.P><TXT>In other words, what the case-law seems to me to be primarily concerned with is the <HT TYPE="ITALIC">quality</HT> of the data relied on (in terms of its credibility, accuracy, and relevance), not necessarily the <HT TYPE="ITALIC">origin</HT> of the data (national or international). Whether or not full risk assessments in practice rely on sources from 1, 2 or 10 countries appears rather irrelevant in itself. What is relevant is whether the data relied on is convincing and not contradicted by other significant stream of research.</TXT></NP.ECR><?PAGE NO="15"?><NP.ECR IDENTIFIER="NP0090"><NO.P>90.</NO.P><TXT>Whether or not an individual national administrative decision meets such requirements is a factual issue, to be addressed by the national courts when evaluating scientific evidence put before them. It is fair to acknowledge, however, that in practical terms, is difficult to conceive that in a highly specialised field of research as is the impact on human health of vitamins and minerals, all the most up-to-date and relevant research would be contained within a single Member State and could therefore all be described as <QUOT.START CODE="2018" REF.END="QE0067" ID="QS0067"/>national opinion<QUOT.END REF.START="QS0067" CODE="2019" ID="QE0067"/>. It certainly begs the question what, in today’s increasingly interconnected world of research, such a notion would entail.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0046"><P>Is <QUOT.START CODE="2018" REF.END="QE0068" ID="QS0068"/>national<QUOT.END REF.START="QS0068" CODE="2019" ID="QE0068"/> scientific opinion defined <HT TYPE="ITALIC">institutionally</HT> (because it was generated and adopted by a national body) or <HT TYPE="ITALIC">substantively</HT> (because a decision relies, at least formally, only on science of <QUOT.START CODE="2018" REF.END="QE0069" ID="QS0069"/>national<QUOT.END REF.START="QS0069" CODE="2019" ID="QE0069"/> origin)? As an entirely hypothetical example, is it still a <QUOT.START CODE="2018" REF.END="QE0070" ID="QS0070"/>national<QUOT.END REF.START="QS0070" CODE="2019" ID="QE0070"/> scientific opinion, if it was signed off by its director-general of Belgian origin? What if the scientific committee included a Canadian national? What if the opinion draws on research by labs in France, employing researchers from across the globe? What if the seemingly <QUOT.START CODE="2018" REF.END="QE0071" ID="QS0071"/>national<QUOT.END REF.START="QS0071" CODE="2019" ID="QE0071"/> studies quoted in a <QUOT.START CODE="2018" REF.END="QE0072" ID="QS0072"/>national<QUOT.END REF.START="QS0072" CODE="2019" ID="QE0072"/> opinion of an administrative authority themselves actually rely on and incorporate into their own substantive argument international studies? In an increasingly intertwined and interconnected world, certainly in some areas of (exact) sciences, it is unclear what would qualify strictly speaking as <QUOT.START CODE="2018" REF.END="QE0073" ID="QS0073"/>national scientific opinion<QUOT.END REF.START="QS0073" CODE="2019" ID="QE0073"/>, and, above all, what would be the practical utility of such a distinction. Fortunately, replying to the national court’s third question does not require a detailed exploration of that thorny issue.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0091"><NO.P>91.</NO.P><TXT>However, such a possibility cannot be completely excluded. If it does exist, I consider it would be simply wrong to argue solely on that basis that the Member State has not conducted a full risk assessment. Conversely, the simple fact that a risk assessment <HT TYPE="ITALIC">does</HT> refer to non-national scientific opinion should obviously not be taken as meaning that the assessment is comprehensive. Again, this is in practice a factual assessment of the quality and comprehensiveness of individual research, which may or may not coincide with national boundaries.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0092"><NO.P>92.</NO.P><TXT>In the light of the above, I do not consider that EU law contains an absolute requirement for risk assessments always to be based on international opinion.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0093"><NO.P>93.</NO.P><TXT>Finally, the fact that international research indicates that higher amounts of nutrients are acceptable in food supplements without any risk for human health is not decisive to the extent that the risk assessment is comprehensive and takes into account the most relevant and recent evidence, whether national or international.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0047"><P>It may be that international research points to lower acceptable maxima than national research and that would not be a reason for ignoring it either.</P></NOTE></TXT></NP.ECR><NP.ECR IDENTIFIER="NP0094"><NO.P>94.</NO.P><TXT>EU law requires Member States to ensure that, before adopting restrictions, a full risk assessment is conducted. Any restrictions based on that assessment must be necessary and proportionate. However, EU law does not require Member States to come to the same conclusions in its assessment or to apply the same restrictions. <HT TYPE="ITALIC">A fortiori,</HT> nor does it require Member States to align their conclusions and restrictions with those of the most <QUOT.START CODE="2018" REF.END="QE0074" ID="QS0074"/>permissive<QUOT.END REF.START="QS0074" CODE="2019" ID="QE0074"/> Member State. Were it otherwise, the discretion retained by Member States in that regard would be negated.<NOTE TYPE="FOOTNOTE" NUMBERING="ARAB" NUMBERING.CONTINUED="YES" NOTE.ID="E0048"><P>Judgments of <REF.DOC.ECR><DATE ISO="20030923">23 September 2003</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">Denmark</HT></NAME.CASE> (<NO.CASE>C‑192/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2003:492">EU:C:2003:492</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0042">42</REF.NP.ECR> and <REF.NP.ECR REF="NP0043">43</REF.NP.ECR></REF.DOC.ECR>); of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Commission</HT> v <HT TYPE="ITALIC">France</HT></NAME.CASE> (<NO.CASE>C‑24/00</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:70">EU:C:2004:70</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0049">49</REF.NP.ECR> and <REF.NP.ECR REF="NP0050">50</REF.NP.ECR></REF.DOC.ECR>); of <REF.DOC.ECR><DATE ISO="20040205">5 February 2004</DATE>, <NAME.CASE><HT TYPE="ITALIC">Greenham and Abel</HT></NAME.CASE> (<NO.CASE>C‑95/01</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:2004:71">EU:C:2004:71</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0037">37</REF.NP.ECR> and <REF.NP.ECR REF="NP0038">38</REF.NP.ECR></REF.DOC.ECR>); and of <REF.DOC.ECR><DATE ISO="19830714">14 July 1983</DATE>, <NAME.CASE><HT TYPE="ITALIC">Sandoz</HT></NAME.CASE> (<NO.CASE>174/82</NO.CASE>, <NO.ECLI ECLI="ECLI:EU:C:1983:213">EU:C:1983:213</NO.ECLI>, paragraphs <REF.NP.ECR REF="NP0016">16</REF.NP.ECR> and <REF.NP.ECR REF="NP0017">17</REF.NP.ECR></REF.DOC.ECR>).</P></NOTE> Mutual recognition would effectively be transformed from a fundamental principle into an absolute obligation for Member States.</TXT></NP.ECR><NP.ECR IDENTIFIER="NP0095"><NO.P>95.</NO.P><TXT>In the light of the above, I propose to reply to the national court’s third question as follows:</TXT><P>Article 34 TFEU and Directive 2002/46 do not preclude, as a matter of principle, national legislation which set maximum amounts for vitamins and minerals allowed in food supplements on the sole basis of national scientific opinions. Article 34 TFEU and Directive 2002/46 do not require Member States to align such maximum amounts with recent international scientific opinions for the sole reason that those opinions foresee safe maxima that are higher than those foreseen in national scientific opinions in (under) the same condition of use. It is for the national court to decide whether, on the facts of the case, the national measure at issue is based on a full risk assessment based on the most recent and relevant scientific data available, be it national or international.</P></NP.ECR></GR.SEQ></GR.SEQ><?PAGE NO="16"?><GR.SEQ LEVEL="1"><TITLE><TI><NP><NO.P><HT TYPE="BOLD">V –</HT></NO.P><TXT><HT TYPE="BOLD">Conclusion</HT></TXT></NP></TI></TITLE><NP.ECR IDENTIFIER="NP0096"><NO.P>96.</NO.P><TXT>In the light of the above, I propose to reply to the questions posed by the Tribunal de grande instance de Perpignan (Regional Court, Perpignan) as follows:</TXT><P><QUOT.S LEVEL="1"><GR.SEQ LEVEL="1"><TITLE><TI><P>Question 1</P></TI></TITLE><P>Article 34 TFEU and the principle of mutual recognition, read in the light of Directive 2002/46/EC of the European Parliament and of the Council of <DATE ISO="20020610">10 June 2002</DATE> on the approximation of the laws of the Member States relating to food supplements, preclude a national rule, which prohibits importation of food supplements lawfully produced or marketed in another Member State, on the basis that those food supplements contain a nutrient in quantities exceeding a given maximum, where such maximum has been fixed without a prior scientific risk assessment guided in particular by the criteria laid down in Article 5(1) and (2) of that directive. Where such a prior risk assessment has been conducted, Article 34 TFEU and the principle of mutual recognition, read in the light of Directive 2002/46, require Member States to allow importers to seek revision of that prior risk assessment on the basis of scientific evidence not previously taken into account by the Member State. Procedures for reviewing such new scientific evidence must be readily accessible, completed within a reasonable time and the resulting decisions must be open to challenge before national courts.</P></GR.SEQ><GR.SEQ LEVEL="1"><TITLE><TI><P>Question 2</P></TI></TITLE><P>Article 34 TFEU and the principle of mutual recognition, read in the light of Directive 2002/46, preclude a national rule, which prohibits importation of food supplements lawfully produced or marketed in another Member State, on the basis that those food supplements contain a nutrient in quantities exceeding a given maximum, where such maximum has been fixed without a prior scientific risk assessment guided in particular by the criteria laid down in Article 5(1) and (2) of that directive. Where such a prior risk assessment has been conducted, those principles and provisions of EU law do not prevent presentation of resulting maxima either (a) by group of two or more nutrients or (b) as multiples of recommended daily allowances.</P></GR.SEQ><GR.SEQ LEVEL="1"><TITLE><TI><P>Question 3</P></TI></TITLE><P>Article 34 TFEU and Directive 2002/46 do not preclude, as a matter of principle, national legislation which set maximum amounts for vitamins and minerals allowed in food supplements on the sole basis of national scientific opinions. Article 34 TFEU and Directive 2002/46 do not require Member States to align such maximum amounts with recent international scientific opinions for the sole reason that those opinions foresee safe maxima that are higher than those foreseen in national scientific opinions in (under) the same condition of use. It is for the national court to decide whether, on the facts of the case, the national measure at issue is based on a full risk assessment based on the most recent and relevant scientific data available, be it national or international.</P></GR.SEQ></QUOT.S></P></NP.ECR></GR.SEQ></CONTENTS.CONCLUSION></CONCLUSION>